Pharma and Pandemic

Covid : Moderna devrait gagner 19 milliards de dollars avec son vaccin cette année

La biotech américaine table désormais sur des revenus de 19,2 milliards de dollars contre 18,4 milliards annoncés précédemment grâce à son vaccin ARN.

———————–

Pfizer forecasts $26bn from annual sales of Covid-19 vaccine

Vaccine will generate 73% more than forecast based on contracts signed until mid-April

The US drugmaker Pfizer has smashed its sales forecasts and now expects to bring in $26bn (£19bn) of revenue from its Covid-19 vaccine this year, with its soaraway product accounting for more than a third of the company’s annual income.

The company had expected the vaccine to bring in $15bn over the course of 2021, and the 73% increase in expected revenues to $26bn is still likely to be an underestimate as it counts only orders received by the middle of April and Pfizer is expected to sign more multibillion dollar supply contracts.

————————-

EN DIRECT – Covid : pour BioNTech, suspendre les brevets n’aura pas d’incidence sur la production mondiale

Le laboratoire allemand estime que la protection intellectuelle n’est pas un facteur limitant la production et l’approvisionnement de son vaccin développé avec l’américain Pfizer. Dans le sillage des Etats-Unis, l’Europe et la Russie ont ouvert la porte à une suspension des brevets.

———————

‘Ill-judged’ bonus hike for AstraZeneca boss prompts investor anger

Advisory groups ask shareholders to oppose bid to raise Pascal Soriot’s maximum share bonus to 650% of £1.3m basic pay.

AstraZeneca is facing mounting opposition over its plans to award its chief executive, Pascal Soriot, a big increase in bonuses, with three investor advisory groups calling on shareholders to vote against the policy.

Pirc, Glass Lewis and Institutional Shareholder Services (ISS) have all flagged concerns over moves to raise the maximum share bonus Soriot can receive under a long-term plan from 550% of his £1.3m base salary to 650%. AZ also plans to hoist Soriot’s maximum annual bonus to 250% of salary from 200%, depending on performance targets being hit.

————–

EU ‘ready to discuss’ COVID vaccine patent waiver as drugmakers push back.

The European Union is willing to discuss a proposal to waive intellectual property rights for COVID-19 vaccines, European Commission President Ursula von der Leyen said on Thursday, as drugmakers fought their ground as their share prices tumbled.

U.S. President Joe Biden on Wednesday voiced support for a waiver in a sharp reversal of the U.S. position, and his top trade negotiator, Katherine Tai, swiftly backed negotiations at the World Trade Organization.

———-

Drugmakers say Biden misguided over vaccine patent waiver

Drugmakers on Thursday said U.S. President Joe Biden’s support for waiving patents of COVID-19 vaccines could disrupt a fragile supply chain and that rich countries should instead share more generously with the developing world.

Biden on Wednesday threw his support behind waiving intellectual property rights for COVID-19 vaccines, angering research-based pharmaceutical companies.

———–

Gilead raises 2020 profit forecast on remdesivir strength

Gilead Sciences raised its full-year profit forecast on Monday, as a recent resurgence in Covid-19 cases boosted demand for its Covid-19 treatment, remdesivir.

The level of new Covid-19 cases in the U.S. is starting to rise again, amidst the slow rollout of vaccine. Experts say the country should expect another surge in mid-January due to holiday gatherings.

The antiviral, currently authorized to treat Covid-19 patients across the world, was one of the drugs used to treat U.S. President Donald Trump’s coronavirus infection.

Gilead said it was raising its total product sales forecast to the range of $24.30 billion to $24.35 billion, reflecting increased sales of remdesivir.